Impact of intensive care unit (ICU) drug use on hospital costs: A descriptive analysis, with recommendations for optimizing ICU pharmacotherapy

被引:63
作者
Weber, RJ
Kane, SL
Oriolo, VA
Saul, M
Skledar, SJ
Dasta, JF
机构
[1] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA
[2] UPMC Presbyterian Shadyside, Pittsburgh, PA USA
[3] Univ Pittsburgh, Ctr Pharmacoinformat & Outcomes Res, Pittsburgh, PA USA
[4] Univ Pittsburgh, Ctr Biomed Informat, Pittsburgh, PA USA
[5] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
关键词
intensive care units; drug costs; drug utilization; critical care pharmacists; adverse drug events; pharmacy charges; pharmacoeconomics; drug-use and disease-state management program; total hospital costs; cost-effectiveness analysis;
D O I
10.1097/00003246-200301001-00003
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective. To determine the cost impact of intensive care unit (ICU) drug use on a hospital's total drug expense and to compare ICU pharmacy resource utilization with resource utilization of other hospital departments that provided services to the ICU. Additionally, to suggest strategies, based on these methods and results, to optimize ICU drug use. Methods. Financial transactions for all ICU patients (n = 23,107) treated during fiscal years 1999-2002 were retrieved from the hospital's data repository. ICU drug costs were calculated both as the percentage of total drug costs for each fiscal year and adjusted for hospital volume (ICU patient days). ICU department charges were calculated as a percentage of total ICU charges and analyzed by simple descriptive statistics (mean +/- so). Drug utilization was retrieved for those patients accounting for the highest percentage of ICU pharmacy charges. Main Results: ICU drug costs accounted for 38.4% ( +/-4.1% So) of the total drug costs and have increased at a rate greater than non-ICU drug costs (12% vs. 6%). ICU pharmacy charges accounted for an average of 11.1% (+/-9.2% so) of the total ICU charges, ranking as the fourth most costly of ICU charges. Both costly and highly used ICU therapies were identified for focus on cost-effectiveness analyses or application of an evidence-based drug use and disease state management program model to ICU pharmacotherapy. Conclusions. ICU drug therapies have a significant impact on hospital costs, and effective clinical informatics services and multidisciplinary collaboration programs are necessary to optimize ICU pharmacotherapy.
引用
收藏
页码:S17 / S24
页数:8
相关论文
共 38 条
[21]   IDENTIFYING DRUG USAGE PATTERNS IN THE INTENSIVE-CARE UNIT [J].
MANN, HJ ;
WITTBRODT, ET .
PHARMACOECONOMICS, 1993, 4 (04) :235-239
[22]   Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care [J].
Mascia, MF ;
Koch, M ;
Medicis, JJ .
CRITICAL CARE MEDICINE, 2000, 28 (07) :2300-2306
[23]   Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia [J].
McNabb, JCJ ;
Nightingale, CH ;
Quintiliani, R ;
Nicolau, DP .
PHARMACOTHERAPY, 2001, 21 (05) :549-555
[24]   THE RISING COST OF PHARMACEUTICALS - A DIRECTOR OF PHARMACY PERSPECTIVE [J].
PIERPAOLI, PG .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1993, 50 (08) :S6-S8
[25]  
Rudis MI, 2000, PHARMACOTHERAPY, V20, P1400
[26]   Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit [J].
Rudis, MI ;
Guslits, BJ ;
Peterson, EL ;
Hathaway, SJ ;
Angus, E ;
Beis, S ;
Zarowitz, BJ .
CRITICAL CARE MEDICINE, 1996, 24 (10) :1749-1756
[27]   How to evaluate and interpret outcome studies [J].
Sanchez, LA .
PHARMACOTHERAPY, 2000, 20 (10) :282S-291S
[28]   Projecting future drug expenditures - 2002 [J].
Shah, ND ;
Vermeulen, LC ;
Santell, JP ;
Hunkler, RJ ;
Hontz, K .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (02) :131-142
[29]   Enoxaparin for thromboprophylaxis after major trauma: Potential cost implications [J].
Shorr, AF ;
Ramage, AS .
CRITICAL CARE MEDICINE, 2001, 29 (09) :1659-1665
[30]   Implementation of a drug-use and disease-state management program [J].
Skledar, SJ ;
Hess, MM .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (24) :S23-S29